CVS HEALTH Corp

Company facts

Industry

Retail-Drug Stores and Proprietary Stores

Headquarters

Woonsocket, Rhode Island

Most recent report

8-K, filed Aug 17, 2026

Incorporated

Delaware

Filings on record

1,000+ filings

On EDGAR

CIK 64803

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 2 of 13 sections worth reading, with 9 positive, 6 notable, and 5 negative flags.

• Financial Statements (Item 1)

  Contains full financial results and critical litigation updates that affect future outcomes.
  Notable

  • No share repurchases in H1 2026 despite $11.5B remaining authorization; dividends continue at $0.665/quarter.
  • FTC announced proposed settlement in July 2026 resolving PBM investigations, subject to public comment.
  Negative

  • New $15 million premium deficiency reserve recorded in Q2 2026 for one Medicaid state product line.
  • Opioid litigation accrual remains at $3.4 billion as of June 30, 2026, down from $4.0 billion at March 31, 2026.
  • CVS remains jointly and severally liable for $165 million in the Omnicare False Claims Act case.

• Management's Discussion (Item 2)

  Full MD&A with results, segments, liquidity, and trends. Essential for understanding.
  Positive

  • Total revenues increased $7.2B (7.3%) in Q2 2026, driven by growth across all segments.
  • Operating expenses decreased $166M (1.5%) in Q2 2026 due to absence of $833M litigation charges.
  • Operating income nearly doubled, up $2.3B (97.5%) in Q2 2026 from improved performance and no prior-year litigation.
  • Total revenues increased $13.0B (6.7%) in H1 2026 vs prior year, led by growth across all segments.
  • Operating expenses down $244M (1.1%) in H1 2026 as prior-year charges of $1.2B and $288M did not recur.
  • Operating income increased $3.6B (63.0%) in H1 2026, mainly from Health Care Benefits improvement and no prior-year charges.
  • Health Care Benefits MBR improved 250 bps to 87.4% in Q2 2026, driven by better Government business and no prior-year reserve.
  • Health Care Benefits adjusted operating income surged 85.5% to $2.426B in Q2 2026 on improved Government performance.
  • Net cash provided by operating activities jumped 64.2% to $10.594B in H1 2026 on improved performance and timing.
  Notable

  • Effective tax rate fell to 24.7% in Q2 2026 from 38.5% a year ago, driven by non-deductible charges in prior year.
  • Effective tax rate was 24.8% in H1 2026 vs 34.5% in prior year due to non-deductible litigation charges then.
  • S&P upgraded its outlook on CVS long-term debt from Negative to Stable in May 2026.
  • No shares were repurchased in H1 2026 or H1 2025, despite $11.5B remaining authorized across two programs.
  Negative

  • Utilization is elevated in Q2 2026 and may pressure Health Care Benefits and Health Services if it continues.
  • Total medical membership fell ~700k to 26.0M as of June 30, 2026 vs a year ago due to exit from individual exchange.

What changed: Jun 2026 vs. Mar 2026

About 10% of CVS's Jun 2026 10-Q is new information. 39 paragraphs were added, 141 changed, and 23 removed. Below are the most important lines SECSift identified.

• Item 2 67
• Item 1 61
• Item 6 9
• Item 4 2
• Item 5 1